Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04174196CT.gov A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Solitary Osseous Plasmacytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | Memorial Sloan Kettering Cancer Center | P2 | CCC · 53 |
| Etoposide | Margarida Magalhaes-Silverman | P2 | B |
| Dexasone | Memorial Sloan Kettering Cancer Center | P2 | B |
| Melphalan | Margarida Magalhaes-Silverman | P2 | B |
| Adriamycin | Margarida Magalhaes-Silverman | P2 | B |
| Thalidomide | Margarida Magalhaes-Silverman | P2 | B |
| Bortezomib | Margarida Magalhaes-Silverman | P2 | B |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Margarida Magalhaes-Silverman | P2 | B |
+11 more in the Solitary Osseous Plasmacytoma cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Solitary Osseous Plasmacytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-solitary-osseous-plasmacytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →